Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | DRD3 | P35462 | 2/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12312536 | 1.00 | CYP2D6 (0.54) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL12312535 | 1.00 | CYP2D6 (0.54) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL8105954 | 0.91 | RIPK1 (0.50) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL828538 | 0.83 | HIF1A (0.52) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL3637320 | 0.82 | KCNH2 (0.74) | CYP2D6LMNACYP3A4HTR1AADORA3 | |
| SCHEMBL22957657 | 0.81 | GAA (0.54) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL22957831 | 0.81 | GAA (0.54) | CYP2D6HIF1ALMNACYP3A4HTR1A | |
| SCHEMBL9640997 | 0.81 | ADRB2 (0.73) | CYP2D6HTR1AADORA3SLC6A2SLC6A4 | |
| SCHEMBL25555028 | 0.80 | KDM4E (0.63) | ALDH1A1SMN1; SMN2KMT2AKDM4EL3MBTL1 | |
| SCHEMBL25555118 | 0.80 | KDM4E (0.63) | ALDH1A1SMN1; SMN2KMT2AKDM4EL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-9242975-B2 | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-26 | — | — | US | disclosed |
| US-8987311-B2 | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-03-24 | — | — | US | disclosed |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-02-12 | — | — | US | disclosed |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-01-08 | — | — | US | disclosed |
| US-8263659-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-09-11 | — | — | US | disclosed |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2010-11-25 | — | — | US | disclosed |
| EP-0326869-A2 | Cycloaliphatic ketones, process for their preparation and their use as perfuming and aromatising ingredients | FIRMENICH SA (CH) | 1989-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | CYP2D6 4827/4885HIF1A 1744/4885LMNA 2696/4885 |
| US-20100298276-A1 | THYROID RECEPTOR LIGANDS | TSHR, THRA, THRB | CYP2D6 2057/4885HIF1A 1781/4885LMNA 4844/4885 |
| US-20150045347-A1 | TRIAZOLYL-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK3, IRAK1 | CYP2D6 4540/4885HIF1A 3618/4885LMNA 2436/4885 |
| US-20150011532-A1 | HETEROCYCLIC-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS KINASE INHIBITORS | IRAK4, IRAK1, IRAK2 | CYP2D6 4065/4885HIF1A 4535/4885LMNA 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.